XORTX Therapeutics Brief: Highlighting Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
Trending Stocks Today | Brenmiller Energy Shoots up 132.52% Post-Market
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
XORTX Therapeutics XRTX Research; BioCardia BCDA Device Clearance
Top Midday Gainers
Trending Stocks Today | XORTX Therapeutics Soars 81.73%
Dow Jumps Over 100 Points; Nvidia Earnings Top Views
XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
XORTX Announces Filing and Mailing of the Meeting Documents in Connection With the Annual and Special Meeting of Shareholders
XORTX Therapeutics Schedules Shareholder Meeting
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Stocks in Play: XORTX Therapeutics Inc.
XORTX Therapeutics Adjusts Warrant Terms
XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection With October 2021 US IPO
XORTX Reprices Balance of Warrants Issued in Connection With October 2021 US IPO
Xortx Therapeutics Q1 Financial Snapshot
XORTX Therapeutics | 20-F: FY2023 Annual Report
No Data